BMO Capital Keeps Their Hold Rating on Zoetis (ZTS)


In a report released today, Alex Arfaei from BMO Capital maintained a Hold rating on Zoetis (ZTS). The company’s shares closed on Friday at $95.27, close to its 52-week high of $96.57.

According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.8% and a 72.4% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Eli Lilly & Co.

Currently, the analyst consensus on Zoetis is a Moderate Buy with an average price target of $102.83, a 7.9% upside from current levels. In a report issued on November 2, Morgan Stanley also maintained a Hold rating on the stock with a $100 price target.

.

See today’s analyst top recommended stocks >>

Based on Zoetis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.48 billion and net profit of $347 million. In comparison, last year the company earned revenue of $1.35 billion and had a net profit of $298 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts